<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Proc</journal-id><journal-title-group><journal-title>BMC Proceedings</journal-title></journal-title-group><issn pub-type="epub">1753-6561</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3019404</article-id><article-id pub-id-type="publisher-id">1753-6561-5-S1-O11</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>Early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) significantly enhance survival of severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis: results of the CAMELIA clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Blanc</surname><given-names>Fran&#x000e7;ois-Xavier</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Sok</surname><given-names>Thim</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Laureillard</surname><given-names>Didier</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" corresp="yes" id="A4"><name><surname>Borand</surname><given-names>Laurence</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Rekacewicz</surname><given-names>Claire</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Nerrienet</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Madec</surname><given-names>Yoann</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Marcy</surname><given-names>Olivier</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Chan</surname><given-names>Sarin</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Prak</surname><given-names>Narom</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Kim</surname><given-names>Chindamony</given-names></name><xref ref-type="aff" rid="I8">8</xref><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Kim Lak</surname><given-names>Khemarin</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I10">10</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Hak</surname><given-names>Chanroeurn</given-names></name><xref ref-type="aff" rid="I11">11</xref></contrib><contrib contrib-type="author" id="A14"><name><surname>Dim</surname><given-names>Bunnet</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I9">9</xref><xref ref-type="aff" rid="I12">12</xref></contrib><contrib contrib-type="author" id="A15"><name><surname>Im Sin</surname><given-names>Chhun</given-names></name><xref ref-type="aff" rid="I13">13</xref></contrib><contrib contrib-type="author" id="A16"><name><surname>Sun</surname><given-names>Sath</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I10">10</xref></contrib><contrib contrib-type="author" id="A17"><name><surname>Guillard</surname><given-names>Bertrand</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A18"><name><surname>Sar</surname><given-names>Borann</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A19"><name><surname>Vong</surname><given-names>Sirenda</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A20"><name><surname>Fernandez</surname><given-names>Marcelo</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A21"><name><surname>Fox</surname><given-names>Lawrence</given-names></name><xref ref-type="aff" rid="I14">14</xref></contrib><contrib contrib-type="author" id="A22"><name><surname>Delfraissy</surname><given-names>Jean-Fran&#x000e7;ois</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A23"><name><surname>Goldfeld</surname><given-names>Anne E</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I15">15</xref></contrib></contrib-group><aff id="I1"><label>1</label>Pneumology Unit, Internal Medicine Department, Bic&#x000ea;tre Hospital, Assistance Publique-H&#x000f4;pitaux de Paris, Le Kremlin-Bic&#x000ea;tre, France</aff><aff id="I2"><label>2</label>Cambodian Health Committee, Phnom Penh, Cambodia</aff><aff id="I3"><label>3</label>European Georges Pompidou Hospital, Assistance Publique-H&#x000f4;pitaux de Paris, Paris, France</aff><aff id="I4"><label>4</label>Institut Pasteur in Cambodia, Phnom Penh, Cambodia</aff><aff id="I5"><label>5</label>Agence Nationale de Recherche sur le SIDA et les h&#x000e9;patites virales (ANRS), Paris, France</aff><aff id="I6"><label>6</label>Institut Pasteur, Paris, France</aff><aff id="I7"><label>7</label>Khmer Soviet Friendship Hospital, Infectious Disease Department, Phnom Penh, Cambodia</aff><aff id="I8"><label>8</label>Donkeo Provincial Hospital, Takeo, Cambodia</aff><aff id="I9"><label>9</label>M&#x000e9;decins Sans Fronti&#x000e8;res, Phnom Penh, Cambodia</aff><aff id="I10"><label>10</label>Svay Rieng Provincial Hospital, Svay Rieng, Cambodia</aff><aff id="I11"><label>11</label>Calmette Hospital, Phnom Penh, Cambodia</aff><aff id="I12"><label>12</label>Siem Reap Provincial Hospital, Siem Reap, Cambodia</aff><aff id="I13"><label>13</label>Khmer Soviet Friendship Hospital, Pneumology Department, Phnom Penh, Cambodia</aff><aff id="I14"><label>14</label>Division of AIDS, NIAID, National Institute of Health, Bethesda, USA</aff><aff id="I15"><label>15</label>Immune Disease Institute, Harvard Medical School, Boston, USA</aff><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>10</day><month>1</month><year>2011</year></pub-date><volume>5</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Institut Pasteur International Network Annual Scientific Meeting</named-content><named-content content-type="supplement-editor">Roberto Bruzzone</named-content></supplement><fpage>O11</fpage><lpage>O11</lpage><permissions><copyright-statement>Copyright &#x000a9;2011 Blanc et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>Blanc et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1753-6561/5/S1/O11"/><conference><conf-date>22&#x02013;23 November 2010</conf-date><conf-name>Institut Pasteur International Network Annual Scientific Meeting</conf-name><conf-loc>Hong Kong</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>Tuberculosis (TB) remains the largest cause of death among people living with HIV/AIDS, especially among those with profound immunosuppression. Case-fatality among co-infected patients occurs mainly in the first months after the TB treatment initiation. Therefore, robust data regarding optimal timing of HAART initiation within this early period is critically needed.</p></sec><sec sec-type="methods"><title>Methods</title><p>The CAMELIA (CAMbodian Early vs. Late Introduction of Antiretroviral drugs) clinical trial is an open-labelled randomized clinical trial designed to compare the impact upon mortality of early (2 weeks) vs. late (8 weeks) HAART initiation after TB treatment onset in treatment-na&#x000ef;ve adults with newly diagnosed acid-fast bacilli (AFB) positive TB and CD4+ cell count &#x02264; 200 cells/mm<sup>3</sup>. Patients received standard 6-month TB treatment plus stavudine, lamivudine and efavirenz in 5 hospitals in Cambodia, 2 in Phnom Penh and 3 in province. Patients were followed for 50 weeks after the last patient&#x02019;s enrollment. A log-rank test was used to compare Kaplan-Meier survival curves.</p></sec><sec><title>Results</title><p>661 patients (early, n=332; late, n=329) were enrolled with a median age of 35 yrs, body mass index of 16.7 kg/m<sup>2</sup>, CD4+ cell count of 25 cells/mm<sup>3</sup> and viral load of 5.64 log copies/ml. All AFB-positive samples including sputum in 538 (81.4%) patients, were cultured. As of May 13, 2010, 149 patients were known dead (59, early arm; 90, late arm). Enhanced survival was observed in the early arm (p=0.004, see figure). At week 50, median CD4+ gain was 114 cells/mm<sup>3</sup> and was not statistically different across arms (p=0.22); 96.5% of patients had an undetectable viral load and again no difference across arms was found (0.82). Figure <xref ref-type="fig" rid="F1">1</xref>.</p><fig id="F1" position="float"><label>Figure 1</label><graphic xlink:href="1753-6561-5-S1-O11-1"/></fig></sec><sec><title>Conclusion</title><p>Initiation of HAART 2 weeks after onset of TB treatment significantly improves survival in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis.</p></sec></body><back><sec><title>Acknowledgements</title><p>Supported by grants from ANRS (#1295/12160) and NIH-NIAID (CIPRA KH #001/10425).</p></sec></back></article>